How should I urgently evaluate and manage pleuritic chest pain in a patient with systemic lupus erythematosus and a history of myocarditis?

Urgent Evaluation and Management of Pleuritic Chest Pain in SLE with History of Myocarditis

Perform emergency echocardiography immediately to evaluate for pericardial effusion/tamponade, myocarditis recurrence, and valvular dysfunction, as this patient with SLE and prior myocarditis presenting with pleuritic chest pain requires urgent cardiac imaging to exclude life-threatening complications. 1

Initial Urgent Assessment

Immediate Diagnostic Workup

ECG and cardiac biomarkers must be obtained immediately, even though the history of myocarditis and pleuritic nature suggest pericardial involvement. The differential diagnosis in this specific patient includes:

• Pericarditis (most common cardiac manifestation in SLE, occurring in serositis)
• Recurrent myocarditis (given prior history)
• Myopericarditis (combined involvement)
• Coronary microvascular dysfunction (present in ~50% of SLE patients with chest pain and no obstructive CAD) 2
• Coronary artery disease (21% prevalence in recent SLE chest pain cohort) 3
• Pulmonary embolism (increased risk with SLE, especially if antiphospholipid antibodies present)

Critical Laboratory Tests

Obtain immediately:

• CBC (leukopenia, thrombocytopenia suggest active lupus)
• Serum creatinine and urinalysis (assess for lupus nephritis)
• Complement C3/C4 and anti-dsDNA (markers of disease activity)
• Troponin (elevated in myocarditis/myopericarditis)
• D-dimer if PE suspected
• Antiphospholipid antibodies if not previously documented 4

Emergency Echocardiography Indications

This patient meets multiple Class I indications for emergency echocardiography 1:

1. Acute chest pain with known underlying cardiac disease (prior myocarditis)
2. Suspected pericardial disease (pleuritic pain suggests pericardial involvement)
3. Suspected myopericarditis (explicitly listed indication)
4. Evaluation for pericardial effusion and tamponade

The echocardiogram must assess:

• Pericardial effusion size and hemodynamic significance
• Left ventricular systolic function (compare to prior if available)
• Regional wall motion abnormalities
• Valvular function

Advanced Cardiac Imaging

If echocardiography is non-diagnostic or shows abnormalities requiring further characterization, cardiac MRI should be performed urgently (within 24-48 hours, as diagnostic sensitivity decreases over time). 5, 3

CMR is particularly valuable in this patient because it can:

• Differentiate active myocarditis from prior myocardial injury
• Identify myopericarditis (combined involvement)
• Detect coronary microvascular dysfunction through perfusion mapping
• Rule out ischemia without obstructive CAD (INOCA)

Recent evidence shows CMR altered medical management in 32% of SLE patients with chest symptoms and identified cardiac ischemia (CAD or coronary microvascular dysfunction) more commonly than pericarditis alone. 3

Treatment Algorithm Based on Findings

If Pericarditis Confirmed (No Myocardial Involvement)

• Glucocorticoids are first-line: Prednisone 0.5-1 mg/kg/day 4
• Colchicine 0.5-1 mg daily as adjunct
• NSAIDs may be used cautiously for limited periods in patients at low risk for complications 4

If Myocarditis or Myopericarditis Confirmed

Aggressive immunosuppression is required given the high mortality (40-60% in some series) 6:

• High-dose glucocorticoids: IV methylprednisolone pulse therapy (500-1000 mg daily × 3 days), followed by oral prednisone 1 mg/kg/day 6
• Cyclophosphamide should be added for severe myocarditis (most evidence-based immunosuppressant for this indication) 4, 6
• Rituximab as second-line if inadequate response to cyclophosphamide 6
• Standard heart failure therapy if systolic dysfunction present

If Coronary Ischemia Identified

• Antiplatelet therapy (aspirin) if atherosclerotic CAD
• Anticoagulation if thrombotic mechanism suspected (especially with antiphospholipid antibodies)
• Coronary angiography if obstructive CAD suspected
• Medical management for coronary microvascular dysfunction (beta-blockers, ACE inhibitors, statins)

Critical Pitfalls to Avoid

1. Do not assume pleuritic chest pain is "just pleuritis" in a patient with prior myocarditis—15% of SLE ED visits involve chest pain, and over 50% have non-cardiac causes, but cardiac causes carry high mortality 7

2. Do not delay echocardiography—pericardial tamponade requires immediate recognition and drainage 1

3. Do not miss coronary microvascular dysfunction—present in 14% of recent SLE chest pain cohort and requires specific therapy 3

4. Do not attribute all symptoms to lupus activity without excluding infection—SLE patients have increased infection risk, and infectious pericarditis/myocarditis must be excluded 4

5. Do not use troponin elevation alone to diagnose myocarditis—requires imaging confirmation, as troponin can be elevated in multiple conditions 5

Assessment of Lupus Activity

Serositis (including pericarditis) is a marker of lupus activity and should prompt evaluation for other organ involvement 4:

• Check for concurrent nephritis, neuropsychiatric manifestations, cytopenias
• Low complement and elevated anti-dsDNA support active disease
• Consider increasing baseline immunosuppression (hydroxychloroquine should already be prescribed at ≤5 mg/kg) 8

Disposition

• Admit if any evidence of hemodynamic instability, significant pericardial effusion, myocardial involvement, or active lupus requiring IV therapy
• Discharge with urgent outpatient follow-up only if: normal echocardiogram, normal troponin, stable vital signs, and pain controlled with oral medications
• Ensure rheumatology follow-up within 1-2 weeks regardless of disposition